Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.2.701

XPG is Predictive Gene of Clinical Outcome in Advanced Non-small-cell Lung Cancer with Platinum Drug Therapy  

Zhang, Tian (Department of Radiotherapy, Beijing Chaoyang Hospital, Capital Medical University)
Sun, Jing (Department of Dermatology, The China-Japan Union Hospital of Jilin University)
Lv, Min (Department of Cardiac Surgery, The China-Japan Union Hospital of Jilin University)
Zhang, Lin (Department of Orthopedics, Beijing Shijitan Hospital, Capital Medical University)
Wang, Xia (The Fourth Department of Tuberculosis, the First Affiliated Hospital, Xinxiang Medical College)
Ren, Ji-Chen (Department of Oncology, Tumor Hospital of Jilin Provice)
Wang, Bin (Department of Oncological Surgery, Tumor Hospital of Jilin Provice)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.2, 2013 , pp. 701-705 More about this Journal
Abstract
Polymorphisms in XPG are considered to contribute to the clinical outcome of patients receiving platinum drug chemotherapy. We aimed to investigate the role of five potential SNPs of XPG gene on the response to platinum-based chemotherapy in advanced Chinese NSCLC patients. A total of 451 patients with newly diagnosed and histopathologically confirmed primary NSCLC were consecutively collected. XPG rs2296147, rs4150261, rs17655, rs1047768 and rs2094258 were genotyped by the Taqman real-time polymerase chain reaction (PCR). In our study, we found patients carrying rs1057768 TT genotype had a significantly lower treatment response when compared with the CC genotype (OR=0.38, 95% CI=0.18-0.78). Patients carrying rs1047768 TT genotype showed a significantly short median PFS (11.2 months) and OS (13.6 months) than CC genotype, and the hazard ratios (HR) for PFS and OS were 2.06 (1.01-4.50) and 2.29 (1.21-2.49), respectively. Moreover, we found a significant decreased risk of death from NSCLC among patients carrying the rs2296147 TT genotype when compared with the CC genotype, the HR (95% CI) for OS being 0.50 (0.27-0.95). In conclusion, our study found that polymorphisms in rs1047768 C/T and rs2296147 C/T are associated with response to platinum-based chemotherapy in advanced NSCLC, and XPG polymorphisms could be predictive of prognosis.
Keywords
Non-small-cell lung cancer; xeroderma pigmentosum group G; response; chemotherapy;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Bartolucci R, Wei J, Sanchez JJ, et al (2009). XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression. Clin Lung Cancer, 10, 47-52.   DOI   ScienceOn
2 Chang JS, Wrensch MR, Hansen HM, et al (2008) Nucleotide excision repair genes and risk of lung cancer among San Francisco Bay Area Latinos and African Americans. Int J Cancer, 123, 2095-104.   DOI   ScienceOn
3 Chen J, Xie F, Chen K, et al (2009). ERCC5 promoter polymorphisms at -763 and +25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer. Cancer Biol Ther, 8, 1424-30.   DOI
4 Clarkson SG (2003). The XPG story. Biochimie, 85, 1113-21.   DOI   ScienceOn
5 Cordonnier AM, Fuchs RP (1999). Replication of damaged DNA: molecular defect in xeroderma pigmentosum variant cells. Mutat Res, 435, 111-9.   DOI   ScienceOn
6 Fleming ND, Agadjanian H, Nassanian H, et al (2012). Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer. Cancer, 118, 689-97.   DOI   ScienceOn
7 Friedberg EC, Bond JP, Burns DK, et al (2000). Defective nucleotide excision repair in XPC mutant mice and its association with cancer predisposition. Mutat Res, 459, 99-108.   DOI   ScienceOn
8 Friedberg EC (2003). DNA damage and repair. Nature, 421, 436-40.   DOI   ScienceOn
9 Jemal A, Thomas A, Murray T, et al (2002). Cancer statistics, 2002. CA Cancer J Clin, 52, 23-47.   DOI   ScienceOn
10 He C, Duan Z, Li P, Xu Q, et al (2013). Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer. Anticancer Drugs, 24, 300-5.   DOI
11 He J, Qiu LX, Wang MY, et al (2012). Polymorphisms in the XPG gene and risk of gastric cancer in Chinese populations. Hum Genet, 131, 1235-44.   DOI   ScienceOn
12 Liu D, Wu HZ, Zhang YN, et al (2012). DNA repair genes XPC, XPG polymorphisms: relation to the risk of colorectal carcinoma and therapeutic outcome with Oxaliplatin-based adjuvant chemotherapy. Mol Carcinog, 51, E83-93.   DOI   ScienceOn
13 International Agency for Research on Cancer (2008). Lung cancer incidence, Mortality and Prevalence Worldwide in 2008. http://globocan.iarc.fr/factsheet.asp.
14 Molina JR, Yang P, Cassivi SD, et al (2008). Non-small cell lung cancer:epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc, 83, 584-94.   DOI
15 Mudgett JS, MacInnes MA (1990). Isolation of the functional human excision repair gene ERCC5 by intercosmid recombination. Genomics, 8, 623-33.   DOI
16 Nouspikel T, Lalle P, Leadon SA, Cooper PK, Clarkson SG (1997). A common mutational pattern in Cockayne syndrome patients from xeroderma pigmentosum group G: implications for a second XPG function. Proc Natl Acad Sci U S A, 94, 3116-21.   DOI
17 Takahashi E, Shiomi N, Shiomi T (1992). Precise localization of the excision repair gene, ERCC5, to human chromosome 13q32.3- q33.1 by direct R-banding fluorescence in situ hybridization. Jpn J Cancer Res, 83, 1117-9.   DOI
18 Sakano S, Hinoda Y, Sasaki M, et al (2010). Nucleotide excision repair gene polymorphisms may predict acute toxicity in patients treated with chemoradiotherapy for bladder cancer. Pharmacogenomics, 11, 1377-87.   DOI   ScienceOn
19 Sun X, Li F, Sun N, et al (2009). Polymorphisms in XRCC1 and XPG and response to platinumbased chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer, 65, 230-6.   DOI   ScienceOn
20 Tahara E, Yasui W, Ito H, et al (2009). Recent progress in carcinogenesis, progression and therapy of lung cancer: the 19th Hiroshima Cancer Seminar: the 3rd Three Universities' Consortium International Symposium. Jpn J Clin Oncol, 40, 702-8.
21 Walsh CS, Ogawa S, Karahashi H, et al (2008). ERCC5 is a novel biomarker of ovarian cancer prognosis. J Clin Oncol, 26, 2952-8.   DOI   ScienceOn
22 Wood RD, Mitchell M, Sgouros J, et al (2001) Human DNA repair genes. Science, 291, 1284-9.   DOI   ScienceOn
23 Zhang L, Gao G, Li X, et al (2012). Association between single nucleotide polymorphisms (SNPs) and toxicity of advanced non-small-cell lung cancer patients treated with chemotherapy. PLoS One, 7, e48350.   DOI